Targeted therapy for lung cancer: present and future

Charu Aggarwal

Hematology-Oncology Division, Department of Medicine, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA

Correspondence to: Charu Aggarwal, MD, MPH. Assistant Professor, Hematology-Oncology Division, Department of Medicine, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA. Email: Charu.Aggarwal@uphs.upenn.edu.

Abstract: Recent advances in methods of genomic profiling have accelerated our understanding of the biology of oncologic diseases. Accumulating evidence suggests that both histology and molecular signature have prognostic and predictive value. Advances in molecular characterization of solid tumors have made individualized approaches feasible. Personalized chemotherapy and targeted biological therapy based on tumor’s individual biologic and molecular profile can optimize efficacy while minimizing toxicity. Molecular testing for activating mutations is routinely performed for several disease subtypes, including non-small cell lung cancer (NSCLC), breast cancer, melanoma and hematological malignancies including CML. For instance, alterations in the epidermal growth factor receptor (EGFR) domain and echinoderm microtubule associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation are routinely used to guide therapeutic decisions for advanced NSCLC. Several new treatments targeting EGFR family members, novel EML4-ALK inhibitors and MEK inhibitors are currently in clinical development. Availability of targeted therapies makes it easier to integrate early palliative and supportive care in the management of patients with advanced malignancies. This review summarizes recent advances in use of targeted therapy, with a focus on NSCLC and a special emphasis on investigational strategies for individualized treatment, especially in patients with metastatic disease.

Keywords: Targeted therapy; lung cancer

Submitted May 31, 2014. Accepted for publication Jun 10, 2014.
doi: 10.3978/j.issn.2224-5820.2014.06.01
View this article at: http://dx.doi.org/10.3978/j.issn.2224-5820.2014.06.01

Introduction

Over the last decade, the oncology field has witnessed significant advances in our understanding of biology of oncologic diseases. Instead of treating a particular histology, or organ system, it is now clear that a cancer with a specific histology represents a constellation of diseases with distinct molecular profiles and sensitivities to treatment. This has largely been boosted by the availability of genomic and transcriptomic profiling, and accessibility of high-throughput and cost-effective readouts of hundreds of individual mutations affecting dozens of cancer genes. Personalized therapy based on patient’s individual biologic and molecular profile is a promising approach to optimize efficacy with the available agents. This understanding has allowed us to deliver targeted therapy, which utilizes agents that affect a known aberrant pathway or molecular target in the cancer cell or tumor microenvironment. Well-documented examples of targeted therapy include the use of trastuzumab to treat HER2-amplified breast cancer (1) and imatinib for BCR-ABL translocated chronic myelogenous leukemia (2). Over the last decade, we have seen an increase in clinical trials of drugs targeting oncoproteins and cancer pathways in various solid tumors. Prominent examples include agents targeting receptor tyrosine kinases (TK), mitogen-activated protein kinase pathway proteins, phosphoinositol-3 kinase (PI3K) pathway components, and the Janus kinase (JAK)—signal transducer and activator of transcription (STAT) pathway. Based on promising activity and improved outcomes, numerous targeted agents have been approved across several disease types. Well-known examples include erlotinib/gefitinib (3) and crizotinib (4) for patients with activating mutations in the epidermal growth factor receptor (EGFR) domain and echinoderm microtubule associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocated non-small cell lung...
cancer (NSCLC) respectively, vemurafenib for melanoma with BRAF V600E mutation (5), lapatinib for HER2 amplified breast cancer (6) and ruxolitinib for patients with JAK-2 mutation (7).

Lung cancer is the most common cause of cancer-related death worldwide (8). NSCLC constitutes the majority of patients diagnosed with lung cancer. Approximately 40% of patients with newly diagnosed NSCLC present with advanced disease, where chemotherapy is the mainstay of treatment. Recently, molecular subtyping of NSCLC has led to approval of and use of targeted therapies in the front-line setting (Table 1). Patients with activating mutations in the EGFR domain and EML4-ALK translocation benefit from first-line treatment with erlotinib or crizotinib, respectively (3,9,10,17). These mutations are seen in a relatively small subset of NSCLC patients. They are common in patients with adenocarcinoma, never smokers and patients of East Asian origin. KRAS is the most common mutation found in NSCLC; however, we currently do not have an effective targeted therapy for this subset of NSCLC. Despite the addition of new therapies, the median 5-year overall survival of patients in advanced staged disease remains a dismal 1-2%.

At the same time, multiple studies have shown that palliative care services improve symptoms, and when incorporated into the treatment management paradigm early, can allow patients achieve a better quality of life, avoid hospitalization. Targeted therapies allow integration of early palliative care into the management of advanced stage diseases, as these therapies are associated with better quality of life, improved symptoms and health status.

This review will focus on current state of targeted treatment approaches for advanced NSCLC, with a special emphasis on novel molecularly targeted agents, and discuss promising agents in development.

### EGFR mutation

EGFR is one of a family of receptors that is over expressed in about 40-80% of NSCLC (18). Mutations in the TK domain of the EGFR receptor were first discovered and reported in 2004 (9,10,19). They are more prevalent in never-smoking patients with adenocarcinoma. In frame deletions in exon 19 and the L858R point mutation in exon 21 are the two most commonly seen activating mutations in the ATP binding pocket of the EGFR TK domain. EGFR mutations significantly predict for both an increased response to TK therapy and a favorable prognosis in patients with advanced lung adenocarcinoma, thereby making the presence of EGFR mutations a powerful prognostic and predictive marker in NSCLC (3,20-24). Erlotinib, which was originally approved in unselected patients in the second and third line setting after progression on platinum-based therapy, is now considered the standard of care for front line treatment of patients whose tumors harbor an activating mutation in the EGFR domain. Beginning with the trial conducted by Mok et al., that randomized previously untreated patients with advanced stage NSCLC with high likelihood of carrying EGFR mutations (adenocarcinoma, never or light smokers) to receive gefitinib or cytotoxic chemotherapy (3), there have been several large, phase III randomized trials that established the place of the EGFR TKIs in the treatment algorithm (3,25).

Across trials, response rates to EGFR TKI vary from 55% to 70%, however, despite this advance, unfortunately median PFS is approximately 9-10 months in most studies with the majority of patients with EGFR mutant tumors sustaining disease progression by 1 year, mostly due to development of resistance by multiple disparate pathways. Rebiopsy at the time of progression has become standard practice, to elucidate the mechanisms of resistance. Emergence of secondary EGFR mutation, T790M, which is resistant to current TKIs (adenocarcinoma, never or light smokers) to receive gefitinib or cytotoxic chemotherapy (3), there have been several large, phase III randomized trials that established the place of the EGFR TKIs in the treatment algorithm (3,25).

<table>
<thead>
<tr>
<th>Genomic alteration</th>
<th>Percentage (%)</th>
<th>Available agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR mutation (activating)</td>
<td>15-20</td>
<td>Erlotinib, afatinib</td>
</tr>
<tr>
<td>KRAS mutation (11)</td>
<td>30</td>
<td>Clinical trials</td>
</tr>
<tr>
<td>EML4 ALK rearrangement (12,13)</td>
<td>5</td>
<td>Crizotinib, ceritinib</td>
</tr>
<tr>
<td>ROS 1 translocation (14)</td>
<td>1-2</td>
<td>Crizotinib</td>
</tr>
<tr>
<td>Her 2 mutation (6)</td>
<td>1-2</td>
<td>Trastuzumab, afatinib</td>
</tr>
<tr>
<td>BRAF mutation (15)</td>
<td>1-3</td>
<td>Dabrafenib</td>
</tr>
<tr>
<td>RET translocation (16)</td>
<td>1</td>
<td>Clinical trials</td>
</tr>
</tbody>
</table>

Data adapted from multiple references (see text) and are estimates only.
kinase, have also been implicated to confer resistance. An understanding of the biology of acquired resistance opens up prospective to develop new therapeutic paradigms.

Afatinib is an oral, irreversible ErbB family inhibitor targeting EGFR and HER2 that has shown activity in erlotinib- and gefitinib-resistant lung cancer models (27). Afatinib has been evaluated in the first line setting against standard chemotherapy (LUX-Lung 3), as well as in patients who had previously been treated with EGFR TKIs (LUX-Lung 1 and 2). LUX-Lung 1 was a randomized, double-blind, phase IIIb/III study that evaluated afatinib vs. placebo plus best supportive care (BSC) in patients who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib (28). Disease control rate at 8 weeks was higher for afatinib at 58% compared with 19% for placebo plus BSC (P<0.0001). Median progression-free survival was longer in the afatinib group (3.3 months) than it was in the placebo group [1.1 months, hazard ratio (HR) =0.38; P<0.0001]. Median overall survival, however, was not different between arms (10.8 vs. 12 months; HR =1.08; P=0.74).

LUX-Lung 2, evaluated the efficacy of afatinib in patients with advanced NSCLC harboring an EGFR-activating mutation (29). In this multicenter, phase II, open-label single-arm study, afatinib was dosed at 40 or 50 mg once daily. For 129 patients that were enrolled, an overall response rate (ORR) of 67% (confirmed ORR of 60%), median PFS of 14 months, and median OS of 24 months was noted. In patients with an exon 19 deletion or a L858R mutation, the objective RR was 69% and 59%, respectively, DCR was 93% and 83%, respectively, and PFS 13.7 and 16.1 months, respectively. Comparable efficacy was observed in the first- and second-line settings.

The LUX-Lung 3 trial compared 40 mg afatinib to intravenous pemetrexed and cisplatin (500+75 mg/m² q21 days up to 6 cycles) as first-line therapy in 345 NSCLC patients harboring an EGFR-activating mutation. ORR was significantly higher with afatinib (56% vs. 23%; P<0.0001). Median PFS was significantly better for afatinib compared with cytotoxic chemotherapy (11.1 vs. 6.9 months; HR =0.58; P=0.0004). In 308 patients with common mutations (Del19/ L858R), median PFS was 13.6 months (30). Based on these results, afatinib was approved by the FDA in August, 2013.

Several new treatments that irreversibly target EGFR family members are under development for patients with NSCLC, most in early clinical phases. Irreversible inhibitors like neratinib (HKI-272) and dacomitinib (PF00299804) have been evaluated. Despite promising preclinical data, neratinib demonstrated marginal activity in both TKI-naïve patients and patients with prior benefit from TKIs, and was therefore discontinued from further development in NSCLC (31). Dacomitinib was studied in a randomized phase II trial in patients with advanced NSCLC previously exposed to platinum-based therapy. One hundred eighty-eight patients were randomly assigned to receive dacomitinib or erlotinib. Even though median PFS was superior [2.8 months for dacomitinib and 1.9 months for erlotinib (HR =0.66; P=0.012)], there was no statistical difference in median OS [9.5 months for dacomitinib and 7.4 months for erlotinib (HR =0.80; 95% CI, 0.56 to 1.13; 2-sided P=0.205)] (32). The overall improvement in PFS seen with dacomitinib was noted across most clinical and molecular subsets assessed. A phase III study [Advanced Research for Cancer Targeted Pan-HER Therapy (ARCHER 1009)] is underway to confirm the findings of this study for second-/third-line therapy in patients with advanced NSCLC (33).

For patients with T790M mutation, combination afatinib and cetuximab has shown promising results. Of 22 patients that were treated, 36% showed partial responses (34). Third generation EGFR TKIs such as CO-1686 have been developed that specifically inhibit the T790M mutant EGFR protein. CO-1686 is currently being tested in a phase I trial in patients with advanced EGFR-mutant NSCLC that have progressed on other EGFR TKIs, where it has shown preliminary evidence of efficacy in resistant disease and a favourable toxicity profile (35). AZD9291 is another third generation EGFR TKI with promising early data in patients with T790M.

MET, another TK, plays an important role in signaling pathways, especially as a resistance mechanism after EGFR TKI blockade. Several MET inhibitors are currently in clinical development. MetMAb is the furthest along in clinical trials. MetMAb (Onartuzumab), a monovalent, single arm monoclonal antibody that binds specifically to the extracellular domain of the MET receptor, blocks ligand mediated activation and further downstream signaling. It was evaluated in combination with erlotinib and compared to erlotinib alone in 128 erlotinib-naïve NSCLC patients whose disease had progressed on one or two prior lines of treatment. In patients with MET overexpression (MET diagnostic positive), PFS (HR =0.56; P=0.05) and OS (HR =0.55; P=0.11) were increased in favor of the combined treatment with MetMAb and erlotinib. Intriguingly, MET diagnostic negative patients receiving both MetMAb and erlotinib had inferior outcomes compared to erlotinib alone.
Besides MET-positive patients, no other subgroup with any clinical benefit from MetMAb was identified (36). Based on these encouraging results, a global randomized phase III trial in MET-diagnostic positive patients is currently ongoing (37).

**EML4-ALK translocation**

ALK is a receptor TK first identified in anaplastic large cell lymphoma. EML4-ALK is a fusion protein in which the N-terminal half of EML4 is fused to the intracellular kinase domain of ALK and leads to expression of a chimeric TK with potent oncogenic activity both *in vivo* and *in vitro* (12,38,39). This translocation causes aberrant activation of downstream oncogenic signaling pathways such as MAP kinase, PI3 kinase, and STAT, leading to cell proliferation, invasion, and inhibition of apoptosis.

In a retrospective genetic screening of 141 NSCLC tumors screened, patients with EML4-ALK mutant tumors were significantly more likely to be younger, male and never/light smokers. An overwhelming majority of the EML4-ALK tumors were adenocarcinomas, and EML4-ALK positivity was associated with resistance to EGFR TKIs (4). Histologically, signet ring features are often present. Even though *EML4-ALK* translocation is found in a limited subset of patients, only 3-6% of all cases of NSCLC, it constitutes 35,000-40,000 cases annually worldwide.

Crizotinib is currently approved for treatment of advanced NSCLC harboring an EML4-ALK translocation. This approval was granted based on response rates of 60% or higher observed in various early clinical studies (17,40). A phase III trial (PROFILE 1007) comparing second-line crizotinib with either pemetrexed or docetaxel in NSCLC with ALK translocation was just completed. Response rate was considerably higher in the crizotinib arm with markedly improved PFS (7.7 months) vs. the control group (3 months). Crizotinib also improved baseline symptoms and delayed subsequent worsening to a greater degree than chemotherapy in quality of life analyses. There was no overall survival benefit seen, most likely because at least 64% of patients in the chemotherapy arm subsequently received crizotinib (13).

In addition, PROFILE 1014, a randomized open-label phase III study of crizotinib vs. pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated metastatic non-squamous cell carcinoma of the lung is currently enrolling patients.

Resistance to crizotinib invariably occurs. Similar to the biology of EGFR resistance, rebiopsy at the time of progression has led to insights into mechanisms of resistance to ALK inhibitors. Mutations in the *ALK* gene appear to mediate resistance in around one-third of patients. Activation of alternate signalling pathways involving *EGFR* and *c-KIT* (an oncogene targeted by imatinib) may also play a role in mediating resistance. In about a third, the mechanism of crizotinib resistance currently remains unknown (41).

Several new ALK inhibitors are under development. Ceritinib (LDK378) is a novel, potent and selective small molecule ALK inhibitor, which does not inhibit c-MET. A phase I study was conducted in patients with tumors with ALK rearrangement, amplification or mutation. Patients received once daily oral ceritinib on a continuous 21-day schedule. A response rate of 81% was reported in 21/26 NSCLC patients treated at ≥400 mg whose disease had progressed following crizotinib. There was also hints of anti-tumor activity against brain metastases at the 750 mg dose (42). The most common AEs included nausea, vomiting and diarrhea (43). Other agents like CH5424802 (93% ORR) and AP26113 are also being studied in clinical trials with promising early results (44).

**KRAS mutation**

Kirsten rat sarcoma viral oncogene is a member of the RAS family and an important downstream signaling target in the survival pathways. Mutations in the *KRAS* gene are the most common mutation seen in adenocarcinomas (about 15-25%). A meta-analysis showed that the mutations were more common in adenocarcinoma than in other histologic types (P value <0.01) and in current or former smokers than in never-smokers (P value <0.01) (45). NSCLC with KRAS mutation forms a distinct subset, and remains a therapeutic challenge; we currently do not have any agents approved for use in this cohort. There has been interest in the development of inhibitors of MEK, a cell signaling pathway downstream from KRAS.

Selumetinib, (an orally available BRAF and MEK inhibitor) has been evaluated in KRAS mutant NSCLC patients who had received prior chemotherapy. On this trial, patients received docetaxel, either alone or in combination with oral selumetinib. OS was numerically longer for selumetinib (9.4 vs. 5.2 months) but did not reach statistical significance (HR =0.80; 80% CI, 0.56; P=0.2069). All secondary endpoints, including RR (37% vs. 0%; P<0.0001) and PFS (Selumetinib 5.3 vs. 2.1 months; P=0.0138), were significantly improved for selumetinib in combination with docetaxel. The combination, however, was also more toxic (11). Based on these promising early data, a phase III trial is currently underway.
Other agents that target driver oncogenes beyond EGFR, ALK and KRAS have also been characterized in NSCLC, often at frequencies of less than 5%. Crizotinib and dabrafenib have shown significant efficacy in patients with ROS-1 (14) translocations and BRAF (15) mutations, respectively (Table 1).

As we identify additional mutations, clinical trial efforts have focused on identifying and matching patients with specific genetic alterations to appropriate therapies within early phase trials.

Conclusions

This review summarizes currently approved targeted therapies and strategies for individualized treatment for patients with advanced NSCLC. In solid tumor oncology, with the availability of modern techniques for whole genome sequencing, we have gained several new insights into disease biology. This knowledge has changed the therapeutic landscape. Molecular characterization is now routinely employed to guide therapeutic decisions, and oral, small molecule inhibitors have firmly secured their place in the treatment paradigm of several solid tumors. Targeted therapies are often associated with improvement in quality of life, and are well tolerated, therefore lending themselves to be perfect partners for early integration to palliative care for management of advanced stage NSCLC.

Acknowledgements

Disclosure: The author declares no conflict of interest.

References
